onc201

ACTION: A randomized phase 3 study of dordaviprone (ONC201) in patients with newly diagnosed H3 K27M-mutant diffuse glioma

American Association for Cancer Research (AACR) Annual Meeting; April 14-19, 2023 –Orlando, FL